Physicochemical 2D-Qsar and 3D Molecular Docking Studies on N-Chlorosulfonyl Isocyanate Analogs as Sterol O-Acyl-Transferase-1 “Soat-1” Inhibitors

DOI: 10.4236/ojmc.2013.34013   PDF   HTML     4,102 Downloads   6,588 Views   Citations

Abstract

A series of N-carbonyl-functionalized ureas, carbamates and thiocarbamates derivatives (or N-Chloro sulfonyl isocyanate
“N-CSI”) were involved in linear and nonlinear physicochemical quantitative structure-activity relationship
“QSAR” analysis to find out the structural keys to control the inhibition against Sterol O-Acyl-Transferase-1 “SOAT-1”.
The results indicate the important effects of geometrical and chemical descriptors on the inhibitory activity of SOAT-1.
The molecules were also screened for three-dimensional molecular docking on the crystal structure of ACAT-1 (1WL5
for ACAT-1, PDB). A comparison between 2D-QSAR and 3D molecular docking studies shows that the latter confirm
the first results and represent a good prediction of the chemical and physical nature of interactions between our drug
molecules and enzyme SOAT-1.

Share and Cite:

K. Akri, R. Mouhibi, M. Zahouily, N. Hanafi and M. Bahlaoui, "Physicochemical 2D-Qsar and 3D Molecular Docking Studies on N-Chlorosulfonyl Isocyanate Analogs as Sterol O-Acyl-Transferase-1 “Soat-1” Inhibitors," Open Journal of Medicinal Chemistry, Vol. 3 No. 4, 2013, pp. 100-120. doi: 10.4236/ojmc.2013.34013.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] N. Khelef, X. Buton, N. Beatini, H. Wang, V. Meiner, T. Y. Chang, R. V. Farese, F. R. Maxfield and I. Tabas, “Immunolocalization of Acyl-Coenzyme A: Cholesterol O-Acyltransferase in Macrophages,” The Journal of Bio-Logical Chemistry, Vol. 273, No. 18, 1998, pp. 11218-11224. http://dx.doi.org/10.1074/jbc.273.18.11218
[2] V. Lather and A. K. Madan, “Predicting Acyl-Coenzyme A: Cholesterol O-Acyltransferase Inhibitory Activity: Computational Approach Using Topologicaldescriptors,” Drug Design and Discovery, Vol. 18, No. 4, 2003, pp. 117-122.
[3] M. A. Diczfalusy, I. Bjorkhem, K. Einarsson and S. E. Alexson, “Acyl-Coenzyme A: Cholesterol O-Acyltransferase Is Not Identical to Liver Microsomal Carboxylesterase,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 16, No. 4, 1996, pp. 606-610. http://dx.doi.org/10.1161/01.ATV.16.4.606
[4] P. Kursula, H. Sikkila, T. Fukao, N. Kondo and R. K. Wierenga, “High Resolution Crystal Structures of Human Cytosolic Thiolase (CT): A Comparison of the Active Sites of Human CT, Bacterial Thiolase, and Bacterial KAS I,” Journal of Molecular Biology, Vol. 347, No. 1, 2005, pp. 189-201. http://dx.doi.org/10.1016/j.jmb.2005.01.018
[5] B. Ferraz-de-Souza, R. E. Hudson-Davies, L. Lin, R. Parnaik, M. Hubank, M. T. Dattani and J. C. Achermann, “Sterol O-Acyltransferase 1 (SOAT1, ACAT) Is a Novel Target of Steroidogenic Factor-1 (SF-1, NR5A1, Ad4BP) in the Human Adrenal,” The Journal of Clinical Endocrinology & Metabolism, Vol. 96, No. 4, 2011, pp. 663-668.
[6] M. R. Lafave, L. Katz, T. Donnon and D. J. Butterwick, “Initial Reliability of the Standardized Orthopedic Assessment Tool (SOAT),” Journal of Athletic Training, Vol. 43, No. 5, 2008, pp. 483-488. http://dx.doi.org/10.4085/1062-6050-43.5.483
[7] K. Hsieh, Y. K. Lee, C. Londos, B. M. Raaka, K. T. Dalen and A. R. Kimmel, “Perilipin Family Members Preferentially Sequester to Either Triacylglycerol-Specific or Cholesteryl-Ester-Specific Intracellular Lipid Storage Droplets,” Journal of Cell Science, Vol. 125, No. 17, 2012, pp. 4067-4076. http://dx.doi.org/10.1242/jcs.104943
[8] W. S. Lee, K.-R. Im, Y.-D. Park, N.-D. Sung and T.-S. Jeong, “Human ACAT-1 and ACAT-2 Inhibitory Activities of Pentacyclictriterpenes from the Leaves of Lycopuslucidus TURCZ,” Biological & Pharmaceutical Bulletin, Vol. 29, No. 2, 2006, pp. 382-384. http://dx.doi.org/10.1248/bpb.29.382
[9] A. Miyazaki, N. Sakashita, O. Lee, K. Takahashi, S. Horiuchi, H. Hakamata, P. M. Morganelli, C. C. Chang and T. Y. Chang, “Expression of ACAT-1 Protein in Human Atherosclerotic Lesions and Cultured Human Monocytes-Macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 18, No. 10, 1998, pp. 1568-1574. http://dx.doi.org/10.1161/01.ATV.18.10.1568
[10] S. Saha, S. R. Bornstein, J. Graessler and S. Kopprasch, “Very-Low-Density Lipoprotein Mediates Transcriptional Regulation of Aldosterone Synthase in Humanadrenocortical Cells,” Cell and Tissue Research, Vol. 348, No. 1, 2012, pp. 71-80. http://dx.doi.org/10.1007/s00441-012-1346-3
[11] Y. Asami, I. Yamagishi, S. Murakami, H. Araki, K. Tsuchida and S. Higuchi, “HL-004, the ACAT Inhibitor, Prevents the Progression of Atherosclerosis in Cholesterol-Fed Rabbits,” Life Sciences, Vol. 62, No. 12, 1998, pp. 1055-1063. http://dx.doi.org/10.1016/S0024-3205(98)00028-9
[12] N. Sakashita, A. Miyazaki, M. Takeya, S. Horiuchi, C. C. Y. Chang, T.-Y. Chang and K. Takahashi, “Localization of Human Acyl-Coenzyme A: Cholesterol Acyltransferase-1 (ACAT-1) in Macrophages and in Various Tissues,” The American Journal of Pathology, Vol. 156, No. 1, 2000, pp. 227-236. http://dx.doi.org/10.1016/S0002-9440(10)64723-2
[13] J. Liao and J. A. Farmer, “Aggressive Statin Therapy and the Risk of Malignancy,” Current Atherosclerosis Re- ports, Vol. 15, No. 4, 2013, p. 316. http://dx.doi.org/10.1007/s11883-013-0316-x
[14] R. A. Kendall, E. Aprà, D. E. Bernholdt, E. J. Bylaska, M. Dupuis, G. I. Fann, R. J. Harrison, J. Ju, J. A. Nichols, J. Nieplocha, T. P. Straatsma, T. L. Windus and A. T. Wong, “High Performance Computational Chemistry: An Overview of NWChem a Distributed Parallel Application,” Computer Physics Communications, Vol. 128, No. 1-2, 2000, pp. 260-283. http://dx.doi.org/10.1016/S0010-4655(00)00065-5
[15] H. Kubinyi, “QSAR and 3D QSAR in Drug Design. Part 1: Methodology,” Drug Discovery Today, Vol. 2, No. 11, 1997, pp. 457-467. http://dx.doi.org/10.1016/S1359-6446(97)01079-9
[16] P. Kolb, R. S. Ferreira, J. J. Irwin and B. K. Shoichet, “Docking and Chemoinformatic Screens for New Ligands and Targets,” Current Opinion in Biotechnology, Vol. 20, No. 4, 2009, pp. 429-436. http://dx.doi.org/10.1016/j.copbio.2009.08.003
[17] L. Xue and J. Bajorath, “Molecular Descriptors in Chemoinformatics, Computational Combinatorial Chemistry, and Virtual Screening,” Combinatorial Chemistry & High Throughput Screening, Vol. 3, No. 5, 2000, pp. 363-372. http://dx.doi.org/10.2174/1386207003331454
[18] J. A. Picard, P. M. O’Brien, D. R. Sliskovic, M. K. Anderson, R. F. Bousley, K. L. Hamelehle, B. R. Krause and R. L. Stanfield, “Inhibitors of Acyl-CoA: Cholesterol O-Acyl-transferase. 17. Structure-Activity Relationships of Several Series of Compounds Derived from N-Chlorosul-fonylisocyanate,” Journal of Medicinal Chemistry, Vol. 39, No. 6, 1996, pp. 1243-1252. http://dx.doi.org/10.1021/jm9509455
[19] X. Li, “A Simulation Evaluation of Backward Elimination and Stepwise Variable Selection in Regression Analysis,” M.S. Thesis, Shandong Polytechnic University, Shandong, 2012.
[20] P. A. Babu, V. T. S. S. Colluru and N. Anaparthy, “In-Silico Characterization of ECE-1 Inhibitors,” Computers in Biology and Medicine, Vol. 42, No. 4, 2012, pp. 446-457. http://dx.doi.org/10.1016/j.compbiomed.2011.12.013
[21] D. J. Livingstone and D. T Manallack, “Statistics Using Neural Networks: Chance Effects,” Journal of Medicinal Chemistry, Vol. 36, No. 9, 1993, pp. 1295-1297. http://dx.doi.org/10.1021/jm00061a023

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.